Fatality, morbidity and quality of life in patients with refractory angina pectoris

Andrell, P.; Ekre, Olof; Grip, Lars; Währborg, Peter; Albertsson, Per; Eliasson, Tore; Jeppsson, Anders; Mannheimer, Clas

doi:10.1016/j.ijcard.2009.09.538

Cited by 58 publications

(45 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ALDH activity was assessed as previously described. 1 Freshly isolated CD133+ fraction and 7 and 15 days cultured CD133+PCs were incubated with 1 mL of Aldefluor staining medium and mixed with 2 µL Aldefluor substrate (Aldegen). Then 500uL of the cells were immediately placed into a tube with 5 µL DEAB (1.5mM) for the negative control, and both tubes of each kind of sample were incubated at 37°C for 50 minutes in dark.…”

Section: Angina: Final Results Of the Progenitor Randomized Trial Promentioning

confidence: 99%

Selected CD133 ⁺ Progenitor Cells to Promote Angiogenesis in Patients With Refractory Angina

Jimenez-Quevedo

González-Ferrer

Sabaté

et al. 2014

Circulation Research

View full text Add to dashboard Cite

Rationale: Refractory angina constitutes a clinical problem.Objective: The aim of this study was to assess the safety and the feasibility of transendocardial injection of CD133+ cells to foster angiogenesis in patients with refractory angina. Methods and Results:In this randomized, double-blinded, multicenter controlled trial, eligible patients were treated with granulocyte colony-stimulating factor, underwent an apheresis and electromechanical mapping, and were randomized to receive treatment with CD133 + cells or no treatment. The primary end point was the safety of transendocardial injection of CD133 + cells, as measured by the occurrence of major adverse cardiac and cerebrovascular event at 6 months. Secondary end points analyzed the efficacy. Twenty-eight patients were included (n=19 treatment; n=9 control). At 6 months, 1 patient in each group had ventricular fibrillation and 1 patient in each group died. One patient (treatment group) had a cardiac tamponade during mapping. There were no significant differences between groups with respect to efficacy parameters; however, the comparison within groups showed a significant improvement in the number of angina episodes per month (median absolute difference, −8.

show abstract

Section: Angina: Final Results Of the Progenitor Randomized Trial Promentioning

confidence: 99%

Selected CD133 ⁺ Progenitor Cells to Promote Angiogenesis in Patients With Refractory Angina

Jimenez-Quevedo

González-Ferrer

Sabaté

et al. 2014

Circulation Research

View full text Add to dashboard Cite

show abstract

“…Eight of these studies focused exclusively on patients with stable angina,12–19 and four included patients with a previous myocardial infarction 12,20–22. Four studies specifically assessed SAQ in patients with advanced IHD unsuitable for revascularization 18,23–25. These studies reported SAQ scores in patients with general angina, or specifically with severe or refractory angina.…”

Section: Resultsmentioning

confidence: 99%

Conversion of the Seattle Angina Questionnaire into EQ-5D utilities for ischemic heart disease: a systematic review and catalog of the literature

Wijeysundera¹,

Farshchi-Zarabi²,

Witteman³

et al. 2014

CEOR

View full text Add to dashboard Cite

BackgroundThere is a paucity of preference-based (utility) measures of health-related quality of life for patients with ischemic heart disease (IHD); in contrast, the Seattle Angina Questionnaire (SAQ) is a widely used descriptive measure. Our objective was to perform a systematic review of the literature to identify IHD studies reporting SAQ scores in order to apply a mapping algorithm to convert these to preference-based scores for secondary use in economic evaluations.MethodsRelevant articles were identified in MEDLINE (Ovid), EMBASE (Ovid), Cochrane Library (Wiley), HealthStar (Ovid), and PubMed from inception to 2012. We previously developed and validated a mapping algorithm that converts SAQ descriptive scores to European Quality of Life-5 Dimensions (EQ-5D) utility scores. In the current study, this mapping algorithm was used to estimate EQ-5D utility scores from SAQ scores.ResultsThirty-six studies met the inclusion criteria. The studies were categorized into three groups, ie, general IHD (n=13), acute coronary syndromes (n=4), and revascularization (n=19). EQ-5D scores for patients with general IHD were in the range of 0.605–0.843 at baseline, and increased to 0.649–0.877 post follow-up. EQ-5D scores for studies of patients with recent acute coronary syndromes increased from 0.706–0.796 at baseline to 0.795–0.942 post follow-up. The revascularization studies had EQ-5D scores in the range of 0.616–0.790 at baseline, and increased to 0.653–0.928 after treatment; studies that focused only on coronary artery bypass grafting increased from 0.643–0.788 at baseline to 0.653–0.928 after grafting, and studies that focused only on percutaneous coronary intervention increased in score from 0.616–0.790 at baseline to 0.668–0.897 after treatment.ConclusionIn this review, we provide a catalog of estimated health utility scores across a wide range of disease severity and following various interventions in patients with IHD. Our catalog of EQ-5D scores can be used in IHD-related economic evaluations.

show abstract

“…12 The significant improvements in 1-year IRA patency and restenosis also reported in DES-treated TOSCA-2 patients likely accounts for this clinical benefit. 5 Angina severity, angina frequency, and revascularization end points have previously been reported to influence quality of life 13,14 and healthcare costs. 15 The presence of collateral flow to the IRA has also been considered a potential determinant of future outcomes and symptoms.…”

Section: Discussionmentioning

confidence: 99%

Long-term outcomes after a strategy of percutaneous coronary intervention of the infarct-related artery with drug-eluting stents or bare metal stents vs medical therapy alone in the Occluded Artery Trial (OAT)

Freixa

Džavík

Forman

et al. 2012

American Heart Journal

View full text Add to dashboard Cite

Background The OAT, a randomized study of routine percutaneous coronary intervention or optimal medical therapy (MED) alone for the treatment of a totally occluded infarct-related artery in the subacute phase after myocardial infarction, showed similar rates of death, reinfarction and congestive heart failure (CHF) between study groups. Although most percutaneous coronary intervention patients were treated with bare metal stents (BMS), drug-eluting stents (DES) were also implanted in the latter part of the study. The aim of the study was to conduct an exploratory analysis of long-term outcomes for DES vs. BMS deployment vs. MED in the OAT. Methods Patients enrolled after February 2003 (when first DES was implanted) were followed (DES n = 79, BMS n = 393, MED n = 552) up to a maximum of 6 years (mean survivor follow-up 5.1 years). Results The 6-year occurrence of the composite end point of death, reinfarction and class IV CHF was similar [20.4% of DES, 18.9% of BMS and 18.4% of MED (P = .66)] as were the rates of the components of the primary end point. During the follow-up period, 33.4% of DES, 44.4% of BMS and 48.1% of MED patients, developed angina (P = .037). The rate of revascularization during follow up was 11.3%, 20.5% and 22.5% among these groups, respectively (P = .045). Conclusions There is no suggestion of reduced long-term risk of death, reinfarction or class IV CHF with DES usage compared to BMS or medical treatment alone. An association between DES use and freedom from angina and revascularization relative to medical therapy is suggested.

show abstract

Fatality, morbidity and quality of life in patients with refractory angina pectoris

Cited by 58 publications

References 32 publications

Selected CD133 ⁺ Progenitor Cells to Promote Angiogenesis in Patients With Refractory Angina

Selected CD133 ⁺ Progenitor Cells to Promote Angiogenesis in Patients With Refractory Angina

Conversion of the Seattle Angina Questionnaire into EQ-5D utilities for ischemic heart disease: a systematic review and catalog of the literature

Long-term outcomes after a strategy of percutaneous coronary intervention of the infarct-related artery with drug-eluting stents or bare metal stents vs medical therapy alone in the Occluded Artery Trial (OAT)

Contact Info

Product

Resources

About

Fatality, morbidity and quality of life in patients with refractory angina pectoris

Cited by 58 publications

References 32 publications

Selected CD133 + Progenitor Cells to Promote Angiogenesis in Patients With Refractory Angina

Selected CD133 + Progenitor Cells to Promote Angiogenesis in Patients With Refractory Angina

Conversion of the Seattle Angina Questionnaire into EQ-5D utilities for ischemic heart disease: a systematic review and catalog of the literature

Long-term outcomes after a strategy of percutaneous coronary intervention of the infarct-related artery with drug-eluting stents or bare metal stents vs medical therapy alone in the Occluded Artery Trial (OAT)

Contact Info

Product

Resources

About

Selected CD133 ⁺ Progenitor Cells to Promote Angiogenesis in Patients With Refractory Angina

Selected CD133 ⁺ Progenitor Cells to Promote Angiogenesis in Patients With Refractory Angina